Cite

HARVARD Citation

    Vodicka, P. et al. (2022). Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma in the real world. European journal of haematology. pp. 162-165. [Online]. 
  
Back to record